Literature DB >> 27313438

More Biologic Therapies Expected To Treat Advanced Plaque Psoriasis.

Chris Fellner.   

Abstract

Psoriasis, a disorder that manifests as a variety of chronic inflammatory skin diseases, affects an estimated 7.4 million Americans. We consider five promising biologic agents poised to enter the psoriasis market for advanced disease by 2019.

Entities:  

Year:  2016        PMID： 27313438      PMCID： PMC4894517     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  32 in total

1.  Biologic therapy for psoriasis: the new therapeutic frontier.

Authors:  Prashant Singri; Dennis P West; Kenneth B Gordon
Journal:  Arch Dermatol       Date:  2002-05

2.  Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease.

Authors:  P Rocha-Pereira; A Santos-Silva; I Rebelo; A Figueiredo; A Quintanilha; F Teixeira
Journal:  Clin Chim Acta       Date:  2001-01       Impact factor: 3.786

Review 3.  Topical treatments for chronic plaque psoriasis.

Authors:  Anne R Mason; James Mason; Michael Cork; Gordon Dooley; Helen Hancock
Journal:  Cochrane Database Syst Rev       Date:  2013-03-28

Review 4.  Topical therapies for localized psoriasis.

Authors:  P M Witman
Journal:  Mayo Clin Proc       Date:  2001-09       Impact factor: 7.616

Review 5.  Pathogenesis and therapy of psoriasis.

Authors:  Michelle A Lowes; Anne M Bowcock; James G Krueger
Journal:  Nature       Date:  2007-02-22       Impact factor: 49.962

6.  Consensus guidelines for the management of plaque psoriasis.

Authors:  Sylvia Hsu; Kim Alexander Papp; Mark G Lebwohl; Jerry Bagel; Andrew Blauvelt; Kristina Callis Duffin; Jeffrey Crowley; Lawrence F Eichenfield; Steven R Feldman; David F Fiorentino; Joel M Gelfand; Alice B Gottlieb; Carmen Jacobsen; Robert E Kalb; Arthur Kavanaugh; Neil J Korman; Gerald G Krueger; Melissa A Michelon; Warwick Morison; Christopher T Ritchlin; Linda Stein Gold; Stephen P Stone; Bruce E Strober; Abby S Van Voorhees; Stefan C Weiss; Karolyn Wanat; Bruce F Bebo
Journal:  Arch Dermatol       Date:  2012-01

7.  Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris.

Authors:  T Henseler; E Christophers
Journal:  J Am Acad Dermatol       Date:  1985-09       Impact factor: 11.527

Review 8.  Psoriasis and streptococci: the natural selection of psoriasis revisited.

Authors:  J P McFadden; B S Baker; A V Powles; L Fry
Journal:  Br J Dermatol       Date:  2009-05       Impact factor: 9.302

9.  Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.

Authors:  Lam C Tsoi; Sarah L Spain; Jo Knight; Eva Ellinghaus; Philip E Stuart; Francesca Capon; Jun Ding; Yanming Li; Trilokraj Tejasvi; Johann E Gudjonsson; Hyun M Kang; Michael H Allen; Ross McManus; Giuseppe Novelli; Lena Samuelsson; Joost Schalkwijk; Mona Ståhle; A David Burden; Catherine H Smith; Michael J Cork; Xavier Estivill; Anne M Bowcock; Gerald G Krueger; Wolfgang Weger; Jane Worthington; Rachid Tazi-Ahnini; Frank O Nestle; Adrian Hayday; Per Hoffmann; Juliane Winkelmann; Cisca Wijmenga; Cordelia Langford; Sarah Edkins; Robert Andrews; Hannah Blackburn; Amy Strange; Gavin Band; Richard D Pearson; Damjan Vukcevic; Chris C A Spencer; Panos Deloukas; Ulrich Mrowietz; Stefan Schreiber; Stephan Weidinger; Sulev Koks; Külli Kingo; Tonu Esko; Andres Metspalu; Henry W Lim; John J Voorhees; Michael Weichenthal; H Erich Wichmann; Vinod Chandran; Cheryl F Rosen; Proton Rahman; Dafna D Gladman; Christopher E M Griffiths; Andre Reis; Juha Kere; Rajan P Nair; Andre Franke; Jonathan N W N Barker; Goncalo R Abecasis; James T Elder; Richard C Trembath
Journal:  Nat Genet       Date:  2012-11-11       Impact factor: 38.330

Review 10.  The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients.

Authors:  Ulrich Mrowietz; James T Elder; Jonathan Barker
Journal:  Arch Dermatol Res       Date:  2006-10-05       Impact factor: 3.017
View more
  1 in total

1.  Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).

Authors:  Andrew Blauvelt; Kim A Papp; Christopher E M Griffiths; Luis Puig; Jamie Weisman; Yves Dutronc; Lisa Farmer Kerr; Dapo Ilo; Lotus Mallbris; Matthias Augustin
Journal:  Am J Clin Dermatol       Date:  2017-04       Impact factor: 7.403
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.